Suppr超能文献

患者对他汀类药物治疗的偏好分布。

Patient Preference Distribution for Use of Statin Therapy.

机构信息

Informed Medical Decisions Program, Massachusetts General Hospital, Boston.

Health Decisions Science Center, Massachusetts General Hospital, Boston.

出版信息

JAMA Netw Open. 2021 Mar 1;4(3):e210661. doi: 10.1001/jamanetworkopen.2021.0661.

Abstract

IMPORTANCE

Thresholds for initiating statin therapy should be informed by patients' preferences.

OBJECTIVE

To define the preference distribution for statin therapy across the spectrum of cardiovascular disease (CVD) risk after participants were informed about the benefits and harms of statin therapy.

DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional survey was conducted from May 13 to June 2, 2020. Participants included 304 individuals aged 40 to 75 years drawn from a nonprobability opt-in panel who had not taken a statin or proprotein convertase subtilisin/kexin type 9 inhibitor in the past 3 years and knew the results of their total cholesterol, high-density lipoprotein cholesterol, and blood pressure measurements.

EXPOSURES

Personalized 10-year CVD risk with and without statin therapy and potential harms of statins.

MAIN OUTCOMES AND MEASURES

The primary outcome was self-reported preference for statin therapy.

RESULTS

The 304 participants had a mean (SD) age of 54.8 (9.9) years; 152 were women (50.0%), 130 (42.8%) non-White, 50 (16.6%) had a high school degree or less education, and 153 (50.8%) reported never needing help reading health materials. When asked their preference for using statin therapy after reviewing their benefit and risk information, 45% of the participants reported they would definitely or probably choose statin therapy. As the risk increased, the proportion who would choose statin therapy generally increased (from 31.1% for a risk <5% to 82.6% for a risk >50%). The minimum risk threshold had to increase to 20% before 75% of respondents in that risk group would want statin therapy. For participants with a risk greater than 10%, the desire to use statin therapy decreased as participants' health literacy, subjective numeracy, and knowledge scores increased.

CONCLUSIONS AND RELEVANCE

In this study, preferences for statin therapy for primary prevention of CVD appeared to vary across the spectrum of 10-year cardiovascular risk, but they were relatively flat at intermediate levels of risk. This preference distribution suggests a broad risk range for shared decision-making.

摘要

重要性

启动他汀类药物治疗的阈值应根据患者的偏好来确定。

目的

在告知患者他汀类药物治疗的益处和危害后,确定心血管疾病(CVD)风险谱中他汀类药物治疗的偏好分布。

设计、地点和参与者:一项横断面调查于 2020 年 5 月 13 日至 6 月 2 日进行。参与者包括从非概率选择小组中抽取的 304 名年龄在 40 至 75 岁之间的个体,他们在过去 3 年内没有服用他汀类药物或前蛋白转化酶枯草溶菌素/克那霉 9 抑制剂,并且知道他们的总胆固醇、高密度脂蛋白胆固醇和血压测量结果。

暴露情况

他汀类药物治疗和不治疗的 10 年 CVD 风险的个性化评估以及他汀类药物的潜在危害。

主要结果和测量

主要结果是报告他汀类药物治疗的自我偏好。

结果

304 名参与者的平均(SD)年龄为 54.8(9.9)岁;152 名女性(50.0%),130 名非白人(42.8%),50 名(16.6%)仅受过高中或以下教育,153 名(50.8%)报告他们阅读健康材料时不需要帮助。在查看了他们的获益和风险信息后,当被问及他们对使用他汀类药物治疗的偏好时,45%的参与者表示他们肯定或可能会选择他汀类药物治疗。随着风险的增加,选择他汀类药物治疗的比例通常会增加(从风险<5%的 31.1%增加到风险>50%的 82.6%)。只有当风险增加到 20%以上时,该风险组中 75%的受访者才会希望使用他汀类药物治疗。对于风险大于 10%的参与者,随着他们的健康素养、主观算术和知识评分的增加,使用他汀类药物治疗的意愿降低。

结论和相关性

在这项研究中,对于 CVD 一级预防的他汀类药物治疗的偏好似乎在 10 年心血管风险谱中有所不同,但在中间风险水平相对平稳。这种偏好分布表明了一个广泛的风险范围,用于共同决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a022/7961307/6f99431807a5/jamanetwopen-e210661-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验